Winner of the 'Biotherapies and Bioproduction' call for projects under the France 2030 plan, EVerZom receives €3 million in government funding to industrialize its exosome bioproduction technology
Winner of the 'Biotherapies and Bioproduction' call for projects under the France 2030 plan, EVerZom receives €3 million in government funding to industrialize its exosome bioproduction technology
Paris, June 17, 2025 – EVerZom, a French biopharmaceutical company pioneering exosome-based therapies for regenerative medicine applications, has announced it has received €3 million in funding as part of the France 2030 plan, through the 'Biotherapies and Bioproduction of Innovative Therapies' call for projects, operated by Bpifrance on behalf of the French government. This financial support will enable the company to accelerate the industrialization of its exosome bioproduction platform to develop its proprietary and co-developed drug candidates.
Accelerating the transition to late-stage clinical production and commercialization
This funding marks a key step in the company's industrial scale-up. It will notably allow for the scale-up of its exosome bioproduction technology in 50L GMP bioreactors, reaching a production level compatible with late-stage clinical phases and market launch.
'The French government 's support through the France 2030 'Biotherapies and Bioproduction' call is a strong recognition of our technology and industrial ambition. Thanks to this funding, we will secure a robust and scalable bioproduction process, which is essential to advance through late-stage clinical phases and prepare the market entry of our future proprietary or co-developed treatments,' said Jeanne Volatron, CEO of EVerZom.
Exosomes at the heart of the development of promising new biotherapies
Exosomes are tiny biological vesicles (30 to 150 nanometers) naturally secreted by cells. They play a key role in intercellular communication, transporting proteins, messenger RNAs, and other functional biomolecules between cells.
EVerZom leverages exosomes derived from mesenchymal stem cells, known for their regenerative and immunomodulatory properties. Compared to the cells themselves, exosomes offer numerous advantages: increased stability, reduced variability, enhanced patient safety, and simplified logistics (direct hospital storage and immediate availability).
EVerGel, EVerZom's first drug candidate for Crohn's disease
EVerZom's flagship program, EVerGel, combines exosomes with an innovative hydrogel biomaterial, enabling prolonged release at the site of complex perianal fistulas—a debilitating condition associated with Crohn's disease that affects nearly 2 million patients worldwide. Initial preclinical results are highly promising: in a porcine model close to the human condition, EVerGel achieved complete healing in 87.5% of cases after 4 weeks, compared to just 12.5% in the control group.
Thanks to these results, the drug candidate could enter clinical trials as early as 2026, with a target commercialization date for 2030.
High potential far beyond the targeted indications
Ultimately, the potential of exosome therapies to regenerate tissue and modulate inflammatory processes opens the door to new applications in a variety of fields, including neurodegenerative diseases, age-related disorders, and regenerative cosmetics. In this context, EVerZom has established around twenty global partnerships with players in human health, animal health, and cosmetics.
Press contact : Florence Portejoie, FP2COM, 06 07 76 82 83, fportejoie@fp2com.fr
About EVerZom
Founded in 2019, EVerZom develops exosome-based treatments derived from mesenchymal stem cells, combined with biomaterials for targeted applications. With a proprietary technology for the production and purification of exosomes, EVerZom aims to address unmet medical needs in chronic inflammatory and degenerative diseases. The company relies on cutting-edge scientific expertise, a network of industrial and academic partners, and a development model focused on pharmaceutical quality and industrialization. This €3 million funding is part of the France 2030 plan, a French government initiative endowed with €54 billion to support breakthrough innovations and the emergence of technology champions in strategic sectors such as biotechnology.
About France 2030
✔ Embodies a dual ambition: to sustainably transform key sectors of our economy (health, energy, automotive, aerospace, and space) through technological innovation, and to position France not just as a player but as a leader in the world of tomorrow. From basic research to the emergence of an idea through to the production of a new product or service, France 2030 supports the entire innovation lifecycle up to industrialization.
✔ Is unprecedented in its scope: €54 billion are being invested to help our companies, universities, and research organizations successfully transition in these strategic sectors. The goal is to enable them to competitively tackle ecological and attractiveness challenges and foster the emergence of future leaders in our fields of excellence. France 2030 has two transversal objectives: dedicating 50% of its spending to the decarbonization of the economy and 50% to emerging players carrying innovations that are not harmful to the environment (in line with the Do No Significant Harm principle).
✔ Is implemented collectively: designed and deployed in consultation with economic, academic, local, and European stakeholders to determine strategic orientations and flagship actions. Project leaders are invited to submit their applications through open, rigorous, and selective procedures to benefit from State support.
✔ Is managed by the General Secretariat for Investment on behalf of the Prime Minister and implemented by the French Environment and Energy Management Agency (ADEME), the National Research Agency (ANR), Bpifrance, and the Banque des Territoires.
More information: france2030.gouv.fr | @SGPI_avenir
About the 'Innovations in Biotherapies and Bioproduction' call for projects
The 'Innovations in Biotherapies and Bioproduction' call for projects is a support mechanism within the framework of the 'Biotherapies and Bioproduction of Innovative Therapies' acceleration strategy of France 2030, led by the Health Innovation Agency within the General Secretariat for Investment. Its objective is to catalyze and sustain excellence in biotherapy research by accelerating technology transfer and ensuring a constant flow of innovations from bench to bedside.
About Bpifrance
Bpifrance finances businesses at every stage of their development with loans, guarantees, and equity. It supports their innovation and international projects. Bpifrance also backs their export activities through a broad range of products. Advisory services, training, networking, and acceleration programs for startups, SMEs, and mid-caps are also part of the offering. Thanks to Bpifrance and its 50 regional offices, entrepreneurs benefit from a close, single, and efficient contact to support them and help them meet their challenges.
More information: www.bpifrance.fr - https://presse.bpifrance.fr/ - Follow us on X (formerly Twitter): @Bpifrance - @BpifrancePresse and on LinkedIn
Attachment
Everzom_PR_Winner_France_2030_VDEF
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
28 minutes ago
- Bloomberg
Pignataro's ION Plans to Invest in Azimut-Backed Italian Fintech
Andrea Pignataro's ION Group plans to buy a minority stake in a new Italian digital bank backed by private equity firm FSI SGR SpA and asset manager Azimut Holding SpA, according to people familiar with the matter. Pignataro's ION is set to take a roughly 6% stake in the venture, known as TNB, the people said, asking not to be identified discussing private information. Talks are ongoing and the size of the holding could still change, according to the people.
Yahoo
40 minutes ago
- Yahoo
Goldman and Citi See Europe's Economy Powering Stock Rally
(Bloomberg) -- The perils of trade and geopolitics will only slow the rally in European stocks rather than derail it, according to Wall Street strategists. Security Concerns Hit Some of the World's 'Most Livable Cities' One Architect's Quest to Save Mumbai's Heritage From Disappearing JFK AirTrain Cuts Fares 50% This Summer to Lure Riders Off Roads NYC Congestion Toll Cuts Manhattan Gridlock by 25%, RPA Reports Taser-Maker Axon Triggers a NIMBY Backlash in its Hometown The Stoxx Europe 600 Index is expected to end the year around 557 points, according to the average of 19 strategists polled by Bloomberg. That implies a further 3% advance from Wednesday's close, handing investors annual returns of about 10%. Europe's loosening monetary policy and increased government spending are forecast to give the region's stocks the impetus they need to overcome risks from tariffs and rising international tensions. 'Equity markets have been remarkably resilient, despite many risks,' said Citigroup Inc. strategist Beata Manthey. She noted that global equity market valuations reflected relatively average levels of geo-economic risk in the lead up to the Israel-Iran conflict. 'This could be worrisome from a short-term perspective, but over the longer term we see many structural tailwinds to support European equities.' European stocks have posted moderate moves since mid-May, following a V-shaped recovery that erased all the losses triggered by the US tariff announcements of early April. Recent weeks have proved more volatile, as Middle East tensions intensified and pushed oil prices higher. The Stoxx Europe 600 is down 1.5% this month, with energy shares and utilities the only sectors in the green. 'Many investors we are speaking with are awaiting the end of the truce on US tariffs on July 9 to gain better visibility,' said Societe Generale SA strategist Roland Kaloyan. 'Looking ahead, we anticipate that the European equity market will remain within a trading range.' Most strategists have had to chase the rally in Europe as the outlook brightened, updating the cautious price targets they drew up in January. Challenges to so-called US exceptionalism in stocks, Europe's improving economic prospects, as well as a wide interest-rate differential have fueled bets on the region. Bank of America Corp. strategists led by Sebastian Raedler raised their target for the European benchmark on Friday, after the survey was published. They now see the Stoxx Europe 600 reaching 530 points by year-end. The strategists remain relatively negative, but now anticipate a more modest decline, citing better prospects for global PMIs from the partial US-China trade truce. The positive sentiment is also evident among investors. BofA's own fund manager survey conducted this month before Middle East tensions escalated showed that a net 34% of European investors expect stocks in the region to rise in the coming months. While that's broadly unchanged from May, the net proportion expecting gains in the next 12 months has rebounded to the February high of 75%. On a relative basis, asset allocators are increasingly bullish on Europe. A net 34% of portfolio managers in the BofA survey said they are overweight European equities against their funds' benchmark levels — close to a four-year high. A net 36% said they are underweight US equities, nearly the most in two years. While investors haven't lost sight of the risks posed by trade tariffs, they are growing more optimistic about the economy, which will feed into corporate profits, the survey showed. 'Our view is that the diversification theme has further to go,' said Goldman Sachs Group Inc. partner and chief global equity strategist Peter Oppenheimer, adding the weakening dollar favors European assets. 'In total returns, European stocks offer quite a compelling story for investors, especially given their starting point of having very concentrated portfolios, particularly in US equities.' European stocks have outperformed US peers this year, but the gap is narrowing. Renewed appetite for American tech megacaps, potential tax cuts and optimism about trade negotiations helped the S&P 500 erase its losses for 2025 last month. Still, for Deutsche Bank AG strategists led by Maximilian Uleer, who've been consistently bullish on the outlook for the Stoxx 600, tariffs will be a bigger burden for US companies than their European peers. Earnings momentum and valuations are more favorable in Europe, while political uncertainty remains more of a problem, they said. The outlook for fiscal policy and interest rates also favors Europe, while a potential ceasefire between Ukraine and Russia would be an additional boost. 'Once we have more clarity on US tariffs, the One Big Beautiful Bill, the German budget and fiscal package, as well as NATO spending, markets could start moving higher again in late summer,' the Deutsche Bank team said. 'In the medium-term, European equities could start outperforming US equities again.' --With assistance from Jan-Patrick Barnert, Sagarika Jaisinghani and Leslie Nutakor. (Updates with Bank of America's new target and comment in eighth paragraph) Ken Griffin on Trump, Harvard and Why Novice Investors Won't Beat the Pros Is Mark Cuban the Loudmouth Billionaire that Democrats Need for 2028? The US Has More Copper Than China But No Way to Refine All of It Can 'MAMUWT' Be to Musk What 'TACO' Is to Trump? How a Tiny Middleman Could Access Two-Factor Login Codes From Tech Giants ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
40 minutes ago
- Yahoo
Danish Ministry of Digitalization begins testing F2 with open source document editing
Press Release no. 04/2025 Danish Ministry of Digitalization begins testing F2 with open source document editingCopenhagen, June 20, 2025The Danish Ministry of Digitalization has announced the launch of a pilot project to explore digital sovereignty, using cBrain's (NASDAQ: CBRAIN) F2 platform as the foundation for testing an integrated open source alternative to traditional office software. Digitalization Minister Caroline Stage stated: 'We have a political obligation to ensure that our IT systems are not dependent on a few large companies. This pilot is a welcome and concrete first step in that direction.' A group of employees within the ministry's department will begin using F2 with a newly integrated document editing module based on Collabora, the open source solution built on LibreOffice. The pilot will assess whether Collabora, integrated into F2, can meet the ministry's key requirements for document handling such as compatibility with government templates, reliable document conversion, change tracking, and support for advanced formatting. The findings will inform future decisions regarding broader adoption across the ministry. From a technical perspective, cBrain's F2 platform is built on an open architecture that separates data from editing tools. This enables government organizations to use multiple types of editing software in parallel and even allows individual users to choose their preferred editing tools while still working collaboratively on the same shared regards Per Tejs Knudsen, CEO Inquiries regarding this Press Release may be directed to Ejvind Jørgensen, CFO & Head of Investor Relations, cBrain A/S, ir@ +45 2594 4973 Attachment Press Release no. 2025-04 (DigMin)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
